VTGN Vistagen Therapeutics, Inc.
Legal ·
A Northern District of California class action names Vistagen, CEO Shawn Singh and COO Joshua Prince. Two derivative suits are stayed behind it, and a separate pro se case was dismissed with prejudice on August 12.
Nasdaq gave Vistagen until February 1, 2027 to restore a $1.00 minimum bid, while its 10-K says its lead Phase 3 study missed the primary endpoint. It used $42.1 million in operations in its last fiscal year.
Nasdaq told Vistagen on Feb 3, 2026, that its stock had closed below $1.00 for 30 consecutive business days. The company has until Aug 3, 2026, to regain compliance, and its last annual report carried a going-concern warning.
Vistagen Therapeutics, Inc. is a late clinical-stage therapeutics company developing and potentially commercializing medicines for social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue and cancer cachexia. Its neuroscience pipeline consists of five clinical-stage intranasal pherine product candidates, each designed to bind peripheral receptors in human nasal chemosensory neurons and activate neurocircuits without requiring systemic absorption or uptake into the brain. The most advanced candidate, fasedienol, is in a U.S. Phase 3 PALISADE program for the acute treatment of social anxiety disorder and has fast track designation from the FDA for that indication. Neither PALISADE-1 nor PALISADE-3 achieved its primary endpoint in the randomized phase, while PALISADE-2 achieved its primary efficacy endpoint in August 2023. Topline results from the randomized portion of PALISADE-4 are expected in the second quarter of calendar 2026. The other candidates are itruvone for major depressive disorder, refisolone for moderate to severe vasomotor symptoms due to menopause, PH15 for psychomotor impairment due to mental fatigue, and PH284 for cancer cachexia.
| Product or program | What it is | Stage |
|---|---|---|
| Fasedienol | Intranasal pherine for acute treatment of social anxiety disorder | U.S. Phase 3 |
| Itruvone | Intranasal pherine for major depressive disorder | |
| Refisolone | Intranasal pherine for moderate to severe menopausal hot flashes | |
| PH15 | Intranasal pherine for psychomotor impairment due to mental fatigue | |
| PH284 | Intranasal pherine for cancer cachexia |
| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Research and development | $55.0 million | $39.4 million |
| Net income (loss) | -$69.7 million | -$51.4 million |
| Cash from operations | -$66.4 million | -$42.1 million |
| Cash and equivalents | $30.8 million | $67.1 million |
| Short-term investments | $14.6 million | $13.4 million |
Our latest story on this, dated Aug 14, 2026: "Vistagen faces securities class action and two derivative suits over PALISADE-3 trial statements". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 6, 2026: "Vistagen gets Nasdaq minimum bid price deficiency notice, with until August 3, 2026 to comply". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 6, 2026: "Vistagen gets Nasdaq minimum bid price deficiency notice, with until August 3, 2026 to comply". The story links the filing or release it is based on. Read the story.
Vistagen Therapeutics, Inc. trades under the ticker VTGN on NASDAQ.
Vistagen Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Vistagen Therapeutics, Inc. is 1411685. Its filings are on SEC EDGAR.
44,376,911 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Vistagen Therapeutics, Inc. under United States.
Our directory classifies Vistagen Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Vistagen Therapeutics, Inc. is US92840H4002.
aibio.space lists Vistagen Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Vistagen Therapeutics, Inc. is a late clinical-stage therapeutics company developing and potentially commercializing medicines for social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue and cancer cachexia. Its neuroscience pipeline consists of five clinical-stage intranasal pherine product candidates, each designed to bind peripheral receptors in human nasal chemosensory neurons and activate neurocircuits without requiring systemic absorption or uptake into the brain.
Fasedienol: Intranasal pherine for acute treatment of social anxiety disorder Stage: U.S. Phase 3.
Itruvone: Intranasal pherine for major depressive disorder
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 8.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio